7 Hills Pharma

7 Hills Pharma is a clinical-stage pharmaceutical company developing first-in-concept, oral immune stimulants to augment a broad range of immunotherapies for the treatment of drug-resistant solid tumors and prevention of infectious diseases. Our compounds are selective, allosteric, systemic activators of the integrins LFA-1 and VLA-4 that have been shown in preclinical models to augment the effectiveness of prophylactic vaccines for influenza, COVID-19, Tuberculosis, and Chagas disease, as well as checkpoint inhibitors for solid tumors. Our lead molecule, 7HP349, has completed a Phase I first-in-human clinical trial, demonstrating oral bioavailability and an exceptional safety profile at exposures well exceeding therapeutic levels.